[go: up one dir, main page]

MX2014006990A - Tratamiento para diabetes tipo i y tipo ii. - Google Patents

Tratamiento para diabetes tipo i y tipo ii.

Info

Publication number
MX2014006990A
MX2014006990A MX2014006990A MX2014006990A MX2014006990A MX 2014006990 A MX2014006990 A MX 2014006990A MX 2014006990 A MX2014006990 A MX 2014006990A MX 2014006990 A MX2014006990 A MX 2014006990A MX 2014006990 A MX2014006990 A MX 2014006990A
Authority
MX
Mexico
Prior art keywords
type
diabetes
treatment
mammal
effective amount
Prior art date
Application number
MX2014006990A
Other languages
English (en)
Other versions
MX359171B (es
Inventor
Andrew G Reaume
Michael S Saporito
Alexander R Ochman
Original Assignee
Melior Pharmaceuticals I Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Melior Pharmaceuticals I Inc filed Critical Melior Pharmaceuticals I Inc
Publication of MX2014006990A publication Critical patent/MX2014006990A/es
Publication of MX359171B publication Critical patent/MX359171B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona métodos para tratar diabetes tipo I o tipo II en un mamífero mediante la administración de una cantidad eficaz de insulina y una cantidad eficaz de un compuesto de fenoxipirimidinona al mamífero en necesidad de este tratamiento, y formulaciones para llevar a cabo los métodos.
MX2014006990A 2011-12-12 2012-12-12 Tratamiento para diabetes tipo i y tipo ii. MX359171B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161569496P 2011-12-12 2011-12-12
PCT/US2012/069072 WO2013090319A2 (en) 2011-12-12 2012-12-12 Treatment of type i and type ii diabetes

Publications (2)

Publication Number Publication Date
MX2014006990A true MX2014006990A (es) 2015-02-05
MX359171B MX359171B (es) 2018-09-18

Family

ID=48613352

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014006990A MX359171B (es) 2011-12-12 2012-12-12 Tratamiento para diabetes tipo i y tipo ii.

Country Status (14)

Country Link
US (2) US20150190396A1 (es)
EP (1) EP2790704B1 (es)
JP (1) JP6152387B2 (es)
KR (1) KR102069395B1 (es)
CN (2) CN107007608B (es)
AU (2) AU2012352480A1 (es)
BR (1) BR112014014289A2 (es)
CA (1) CA2859156C (es)
IL (1) IL233004B (es)
MX (1) MX359171B (es)
RU (1) RU2646475C2 (es)
SG (2) SG11201403207WA (es)
WO (1) WO2013090319A2 (es)
ZA (1) ZA201404738B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10863264B2 (en) 2017-01-23 2020-12-08 David Sampson Vibration inducing tactile apparatus
CN111587245B (zh) * 2018-01-11 2023-10-31 富光药品株式会社 大规模制备托利咪酮的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3922345A (en) 1971-10-29 1975-11-25 Pfizer Pyrimidinones and hydroxy pyrimidines
SE9203753D0 (sv) 1992-12-11 1992-12-11 Kabi Pharmacia Ab Expression system for producing apolipoprotein ai-m
SE9500778D0 (sv) 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
US6037323A (en) 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US20030198666A1 (en) * 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US20070025953A1 (en) * 2005-07-27 2007-02-01 Jones Michael R Co-therapy for diabetic conditions
EP1924262B1 (en) * 2005-08-22 2011-11-16 Melior Pharmaceuticals I, Inc. Methods and formulations for modulating lyn kinase activity and treating related disorders
RU2316339C1 (ru) * 2006-09-13 2008-02-10 Общество С Ограниченной Ответственностью "Концерн О3" Способ получения препарата инсулина для перорального применения
CA2678813A1 (en) * 2007-02-20 2008-08-28 Melior Pharmaceuticals I, Inc. Methods of identifying activators of lyn kinase
US20100197710A1 (en) * 2007-07-23 2010-08-05 Melior Pharmaceuticals I, Inc. Methods Of Activating IRS-1 And AKT
SI2355829T1 (sl) * 2008-12-12 2015-03-31 Poxel S.A.S. Kombinacija inzulina z derivati triazina in njegova uporaba za zdravljenje diabetesa
WO2011150300A1 (en) * 2010-05-28 2011-12-01 Melior Pharmaceuticals I, Inc. Prevention of pancreatic beta cell degeneration
CN110785170B (zh) * 2017-04-10 2023-03-28 梅里奥尔医药I公司 脂肪细胞的治疗

Also Published As

Publication number Publication date
JP6152387B2 (ja) 2017-06-21
WO2013090319A2 (en) 2013-06-20
CN104271140B (zh) 2016-11-23
EP2790704A4 (en) 2015-09-02
CA2859156C (en) 2020-10-06
SG10201604828QA (en) 2016-07-28
AU2017204652A1 (en) 2017-07-27
IL233004A0 (en) 2014-07-31
CN104271140A (zh) 2015-01-07
HK1202819A1 (en) 2015-10-09
SG11201403207WA (en) 2014-09-26
CA2859156A1 (en) 2013-06-20
AU2017204652B2 (en) 2018-08-16
US20150190396A1 (en) 2015-07-09
CN107007608A (zh) 2017-08-04
MX359171B (es) 2018-09-18
US20200215068A1 (en) 2020-07-09
BR112014014289A8 (pt) 2017-06-13
EP2790704A2 (en) 2014-10-22
RU2646475C2 (ru) 2018-03-05
KR102069395B1 (ko) 2020-01-22
JP2015513310A (ja) 2015-05-07
KR20140107416A (ko) 2014-09-04
WO2013090319A3 (en) 2014-12-04
BR112014014289A2 (pt) 2017-06-13
NZ626495A (en) 2016-03-31
IL233004B (en) 2020-01-30
CN107007608B (zh) 2021-04-23
RU2014128528A (ru) 2016-02-10
AU2012352480A1 (en) 2014-07-17
ZA201404738B (en) 2016-10-26
EP2790704B1 (en) 2019-04-03

Similar Documents

Publication Publication Date Title
PH12013501688A1 (en) Treatment of amyotrophic lateral sclerosis using umbilical derived cells
UA117451C2 (uk) Терапевтично активні сполуки і способи їх застосування
PH12014501702A1 (en) Imidazopyrrolidinone compounds
AU2011328009A8 (en) Compounds and methods for treating pain
MX2013011922A (es) Compuestos de benceno substituido.
EA033067B1 (ru) Способ лечения метаболических расстройств у пациента, имеющего противопоказание к назначению бигуанидного соединения
EA201500019A1 (ru) Способ лечения gd2-положительного рака
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
PH12013502144A1 (en) Multiple myeloma treatment
EA202091676A1 (ru) Способ лечения потери костной массы альвеолярного отростка посредством применения антител к склеростину
SG178596A1 (en) Methods of treatment using anti-oxidized ldl antibodies
IN2014DN03464A (es)
MX2013010050A (es) Inhibidor de proteasoma delanzomib para uso en el tratamiento de lupus.
PH12014502065A1 (en) Vesicular formulations
UA113859C2 (xx) Похідні спіротієнопіранпіперидину як антагоністи рецептора orl-1 для їх застосування при лікуванні алкогольної залежності та зловживання алкоголем
EP2597949A4 (en) SUBMIKROMETERZUSAMMENSETZUNGEN
MX2011012538A (es) Terapia de combinacion para el tratamiento del mieloma multiple.
AU2012240388A8 (en) Treatment regimens
MX359171B (es) Tratamiento para diabetes tipo i y tipo ii.
MX2014006255A (es) Tratamientos neurologiocos con metaloporfirina.
PH12015501980A1 (en) Pyrroloquinolinyl-pyrrolidine-2,5-dione formulations and methods for preparing and using same
WO2011097027A3 (en) Methods for treating or inhibiting infection by clostridium difficile
BR112012006073A2 (pt) composições e métodos para tratar espasticidade.
NZ750581A (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
UA80369U (ru) Способ лечения мультирезистентного туберкулеза легких

Legal Events

Date Code Title Description
FG Grant or registration